These are the five stocks to watch heading into Friday, November 6, 2026. Each received a bullish rating change or new coverage on Thursday, November 5. The market's direction changed sharply over two sessions. On Wednesday, November 4, the Dow Jones Industrial Average jumped 1,569.40 points, or 3.03%, to 53,356.12. The S&P 500 rose 1.58% to 7,688.62, and the Nasdaq Composite gained 1.44% to 25,736.51, after Democrats won control of both chambers of Congress. Selling returned on Thursday, November 5. By early afternoon, the Nasdaq was down about 5% and had fallen into correction territory, and the S&P 500 had lost more than 3%. Investors worried that the new Congress could slow construction of AI data centers. Nvidia fell about 7.5% and AMD about 14.6%. The October jobs report is due November 6.
The five ideas below span solar panels, outdoor building products, movie theaters, aerospace materials, and lab testing. Editorial notes only, not investment advice.
First Solar (FSLR) – William Blair Upgrades the U.S. Solar Panel Maker
William Blair analyst Jed Dorsheimer upgraded First Solar from Market Perform to Outperform on Thursday, citing the midterm results. He wrote that the outcome should unlock more local support for utility-scale solar procurement and siting. In our view, a company that builds panels in the U.S. could benefit if federal permitting for solar projects becomes faster.
Shares traded near $194.96 during Thursday's session, up about 0.23%, giving First Solar a market capitalization near $21 billion. The 52-week range runs from $165.86 to $320.95. The trailing price-to-earnings multiple is 11.24.
Consensus reads strong buy, with 23 of 28 tracked firms bullish, three neutral, and two bearish. The average price target of $254.32 implies roughly 30% upside. Citigroup's Vikram Bagri kept his Buy rating on November 2 with a $283 target.
Risks: Barclays' Christine Cho cut her target to $230 from $259 on November 2, and two firms rate the stock bearish. Policy timelines, panel pricing, and competition from imports remain factors to monitor.
Trex Company (TREX) – BofA Upgrades the Composite Decking Maker
BofA Securities analyst Rafe Jadrosich upgraded Trex on Thursday, moving it two notches from Underperform to Buy. He raised his price target to $65 from $46. The call followed third-quarter adjusted EBITDA of $100 million, which beat the $91 million consensus estimate. Trex, a maker of composite decking and railings, also raised its 2026 guidance. In our view, BofA's description of Trex as one of the few growth stories in housing heading into 2027 is reasonable, given its margin gains.
Shares traded near $56.60 during Thursday's session, down about 0.96%, giving Trex a market capitalization near $5.8 billion. The stock sits near its 52-week high of $60.21 and well above its low of $29.77. The trailing price-to-earnings multiple is 32.92.
Consensus reads buy, with 13 of 17 tracked firms bullish. The average price target of $54.24 sits below the share price, so the BofA target, implying about 15% upside, is the better guide. Truist's Keith Hughes raised his target to $75 from $60 on November 5.
Risks: Barclays rates the stock Underweight, and three firms are neutral. A rich valuation after a large year-to-date gain and the pace of home remodeling remain factors to monitor.
Cinemark Holdings (CNK) – Morgan Stanley Upgrades the Movie Theater Chain
Morgan Stanley analyst Daniel Duran upgraded Cinemark from Equal Weight to Overweight on Thursday and raised his price target to $50 from $45. He pointed to steady moviegoing, a strong 2027 film slate, and potential capital returns. In our view, Cinemark's valuation of roughly 7 times forward EBITDA, as cited by Morgan Stanley, looks modest for a theater chain whose film supply is growing.
Shares traded near $40.09 during Thursday's session, down about 0.72%, giving Cinemark a market capitalization near $4.6 billion. The stock sits just below its 52-week high of $41.55 and far above its low of $21.60. The trailing price-to-earnings multiple is 16.38.
Consensus reads buy, with six of 10 tracked firms bullish and four neutral. The average price target of $41.10 sits close to the share price, while the Morgan Stanley target implies about 25% upside. Wedbush's Alicia Reese kept her Outperform rating on November 4 with a $46 target.
Risks: Wells Fargo's Omar Mejias rates the stock Equal Weight with a $42 target, and B. Riley is neutral. Film release delays and streaming competition remain factors to monitor.
ATI (ATI) – Citi Initiates the Aerospace Materials Supplier at Buy
Citi initiated coverage of ATI on Thursday with a Buy rating and a $229 price target. The firm said recent volatility in aerospace stocks has created chances to buy high-quality, multi-year growth stories. ATI produces titanium, nickel-based alloys, and other specialty materials used in jet engines, airframes, and defense programs. In our view, ATI's transformation into a supplier focused mainly on aerospace and defense supports Citi's argument.
Shares traded near $166.61 during Thursday's session, down about 6.97% amid the broad market decline, giving ATI a market capitalization near $23 billion. The 52-week range runs from $93.11 to $243.57, and the trailing price-to-earnings multiple is 41.57.
Consensus reads strong buy, with all six tracked firms bullish. The average price target of $228 implies roughly 37% upside, close to Citi's target. KeyBanc's Michael Leshock kept his Overweight rating on October 8 with a $228 target.
Risks: BTIG's Andre Madrid cut his target to $250 from $270 on October 30, and the stock trades well below its high. Aircraft production rates and metals prices remain factors to monitor.
Labcorp Holdings (LH) – HSBC Upgrades the Lab Testing Leader
HSBC upgraded Labcorp from Hold to Buy on Thursday and raised its price target to $410 from $330. The bank cited margin upside, its acquisition strategy, and continued strength in diagnostics. Labcorp runs one of the largest clinical lab networks in the U.S. and also provides central lab services for drug trials. In our view, steady test volumes and a disciplined acquisition strategy support a durable earnings path.
Shares traded near $360.55 during Thursday's session, down about 1.97%, after reaching a new 52-week high earlier in the day. The market capitalization is near $29 billion. The 52-week range runs from $244.52 to $373.34, and the trailing price-to-earnings multiple is 29.58.
Consensus reads strong buy, with eight of 10 tracked firms bullish and two neutral. The average price target of $353.80 sits below the share price, so the HSBC target, implying about 14% upside, is the better guide. UBS's Kevin Caliendo raised his target to $420 from $380 on October 29.
Risks: Barclays' Luke Sergott rates the stock Equal Weight with a $380 target. Medicare lab pricing, the integration of acquisitions, and a stock trading near its high remain factors to monitor.
Found this helpful? Share it with others.